Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.

Published online

Journal Article

Intranasally administered live attenuated influenza vaccine (LAIV) was initially licensed in the United States in 2003 as a trivalent formulation (LAIV3) (FluMist, MedImmune, LLC). Quadrivalent live attenuated influenza vaccine (LAIV4) (FluMist Quadrivalent, MedImmune) has been licensed in the United States since 2012 and was first available during the 2013-14 influenza season, replacing LAIV3. During the 2016-17 and 2017-18 influenza seasons, the Advisory Committee on Immunization Practices (ACIP) recommended that LAIV4 not be used because of concerns about low effectiveness against influenza A(H1N1)pdm09-like viruses circulating in the United States during the 2013-14 and 2015-16 seasons (1,2). On February 21, 2018, ACIP recommended that LAIV4 be an option for influenza vaccination of persons for whom it is appropriate for the 2018-19 season (3). This document provides an overview of the information discussed in the decision-making process leading to this recommendation. A description of methodology and data reviewed will be included in the background materials that will supplement the 2018-19 ACIP Influenza Recommendations, which will replace the 2017-18 ACIP influenza statement (2), and which will also contain guidance for the use of LAIV4.

Full Text

Duke Authors

Cited Authors

  • Grohskopf, LA; Sokolow, LZ; Fry, AM; Walter, EB; Jernigan, DB

Published Date

  • June 8, 2018

Published In

Volume / Issue

  • 67 / 22

Start / End Page

  • 643 - 645

PubMed ID

  • 29879095

Pubmed Central ID

  • 29879095

Electronic International Standard Serial Number (EISSN)

  • 1545-861X

Digital Object Identifier (DOI)

  • 10.15585/mmwr.mm6722a5

Language

  • eng

Conference Location

  • United States